Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C

Area of Science:

• Hepatology
• Pharmacology
• Clinical Medicine

Background:

• Alpha interferon therapy is known to affect serum lipid profiles.
• The impact of newer interferon formulations and combination therapy with ribavirin on triglyceride levels requires further investigation.

Purpose of the Study:

• To evaluate the effect of various forms of alpha interferon, with or without ribavirin, on serum triglyceride and cholesterol levels in patients with chronic hepatitis C.
• To identify factors associated with changes in triglyceride levels during therapy.

Main Methods:

• A review of combined data from prospective, randomized controlled clinical trials.
• Serum triglyceride and cholesterol levels were measured pre- and during therapy in 152 patients with chronic hepatitis C.
• Changes in lipid levels were correlated with baseline characteristics, including HCV genotype and interferon type.

Main Results:

• Serum triglyceride levels increased significantly during alpha interferon therapy, with 12% of patients experiencing levels above 500 mg/dL.
• Triglyceride levels began to decline spontaneously after 12 weeks of therapy and returned to baseline post-treatment.
• Serum cholesterol levels remained largely unchanged throughout the treatment period.

Conclusions:

• Alpha interferon therapy consistently elevates serum triglyceride levels in chronic hepatitis C patients, often to high levels.
• These triglyceride elevations are generally not associated with clinical complications and tend to normalize during therapy and after its completion.
• Baseline triglyceride levels, HCV genotype, and interferon type are factors influencing the rise in triglycerides.